\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationBrussels
Building on Mario Draghi’s urgent call for action to help Europe regain its competitive edge and on President von der Leyen’s vision for a new Life Sciences strategy, this event will be a forum to discuss the role of health in the next EU political cycle.
The event targets stakeholders from the pharmaceutical industry, policymakers, patient advocates, and healthcare experts to discuss how to work together to ensure faster, more equitable access to medicines and how AI is revolutionising health research.
Confirmed speakers include Hans Kluge (WHO Europe), Monica Shaw (BMS), and Lars Fruergaard Jørgensen (Novo Nordisk). Member of European Parliament (MEP) Nicolás González Casares (S&D), MEP Stine Bosse (Renew Europe), and MEP Tomislav Sokol (EPP) will also join us to share the European Parliament’s vision for the life sciences industry in the new mandate.
For the first time, EFPIA is partnering with Similes, a Brussels-based charity dedicated to mental health support, to raise funds for their "Family Home Support" project. EFPIA is committed to matching every euro raised for this charity.
More information and registration on the EFPIA website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
